NASDAQ:AVIR - Nasdaq - US04683R1068 - Common Stock - Currency: USD
2.99
+0.04 (+1.36%)
The current stock price of AVIR is 2.99 USD. In the past month the price increased by 3.82%. In the past year, price decreased by -24.49%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 61.08 | 752.80B | ||
JNJ | JOHNSON & JOHNSON | 15.37 | 372.23B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.96 | 291.20B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.21 | 219.89B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.95 | 218.61B | ||
MRK | MERCK & CO. INC. | 10.69 | 209.51B | ||
PFE | PFIZER INC | 7.45 | 135.72B | ||
SNY | SANOFI-ADR | 14.02 | 132.44B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.76 | 100.94B | ||
GSK | GSK PLC-SPON ADR | 7.05 | 78.52B | ||
ZTS | ZOETIS INC | 26.29 | 69.43B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.67 | 47.30B |
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
ATEA PHARMACEUTICALS INC
225 Franklin Street, Suite 2100
Boston MASSACHUSETTS 02110 US
CEO: Jean-Pierre Sommadossi
Employees: 75
Company Website: https://ateapharma.com/
Investor Relations: https://ir.ateapharma.com/
Phone: 18572048109
The current stock price of AVIR is 2.99 USD. The price increased by 1.36% in the last trading session.
The exchange symbol of ATEA PHARMACEUTICALS INC is AVIR and it is listed on the Nasdaq exchange.
AVIR stock is listed on the Nasdaq exchange.
8 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 104.68% is expected in the next year compared to the current price of 2.99. Check the ATEA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ATEA PHARMACEUTICALS INC (AVIR) has a market capitalization of 255.73M USD. This makes AVIR a Micro Cap stock.
ATEA PHARMACEUTICALS INC (AVIR) currently has 75 employees.
ATEA PHARMACEUTICALS INC (AVIR) has a resistance level at 3. Check the full technical report for a detailed analysis of AVIR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AVIR does not pay a dividend.
ATEA PHARMACEUTICALS INC (AVIR) will report earnings on 2025-05-07, after the market close.
ATEA PHARMACEUTICALS INC (AVIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
The outstanding short interest for ATEA PHARMACEUTICALS INC (AVIR) is 3.93% of its float. Check the ownership tab for more information on the AVIR short interest.
ChartMill assigns a technical rating of 1 / 10 to AVIR. When comparing the yearly performance of all stocks, AVIR is a bad performer in the overall market: 71.56% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to AVIR. While AVIR has a great health rating, there are worries on its profitability.
Over the last trailing twelve months AVIR reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -21.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -36.24% | ||
ROE | -38.37% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 50% to AVIR. The Buy consensus is the average rating of analysts ratings from 8 analysts.